SEC Comment Letter 0000000000-23-001324 to ImmunityBio, Inc. (IBRX) (CIK 0001326110) (IBRX)
ImmunityBio, Inc. (IBRX) (CIK 0001326110)
Date: Feb. 8, 2023 · CIK: 0001326110 · Accession: 0000000000-23-001324
AI Filing Summary & Sentiment
File numbers found in text: 333-269608
Letter
United States securities and exchange commission logo February 8, 2023 David Sachs CFO ImmunityBio, Inc. 3530 John Hopkins Court, San Diego California 92121 Re:ImmunityBio, Inc. Registration Statement on Form S-3 Filed February 7, 2023 File No. 333-269608 Dear David Sachs: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Arzhang Navai at 202-551-4676 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Tom Hornish, Esq.
Show Raw Text
United States securities and exchange commission logo
February 8, 2023
David Sachs
CFO
ImmunityBio, Inc.
3530 John Hopkins Court,
San Diego California 92121
Re:ImmunityBio, Inc.
Registration Statement on Form S-3
Filed February 7, 2023
File No. 333-269608
Dear David Sachs:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Arzhang Navai at 202-551-4676 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Tom Hornish, Esq.